Prophylactic omeprazole reduces antiplatelet associated bleeding

Clopidogrel is now the second most commonly used prescription drug world wide, driven by its adjunctive use in interventional cardiology with aspirin as dual antiplatelet therapy (DAPT). Upper gastrointestinal (GI) bleeding is the most common serious complication associated with the long-term use of DAPT and some observational data have suggested that the prophylactic use of […]

Read More…

Blood transfusion overused following cardiac surgery

Although cardiac surgery is associated with a high rate of allogeneic blood transfusion, evidence about the optimal protocol for blood transfusion for patients undergoing heart surgery is lacking. The rationale for treatment is based on the fact that anaemia is an independent risk factor for morbidity and mortality following cardiac operations, but transfusions themselves have […]

Read More…

Adenosine antagonist fails to improve heart failure symptoms

Deterioration in renal function during the acute treatment of heart failure is a common problem, limiting the ability to up-titrate therapy, and is associated with adverse outcomes. Accrued evidence has implicated physiologically released adenosine as an important mediator of both worsening renal function and diuretic resistance. Adenosine, acting on adenosine A1 receptors in the afferent […]

Read More…

Acute alcohol consumption causes myocardial inflammation

Acute alcohol consumption is known to induce a systemic inflammatory reaction that might lead to alcohol-induced myocardial inflammation. Cardiac Magnetic Resonance Imaging (MRI) is capable of detecting both acute inflammation and fibrosis of the myocardium; the authors of this paper therefore set out to investigate whether binge drinking could indeed induce myocardial inflammation. […]

Read More…

Genetic score improves cardiovascular risk prediction

Genome-wide association studies have found single nucleotide polymorphisms (SNPs) at 13 genomic regions that are associated with coronary artery disease, myocardial infarction, or both. However, genetic discovery studies have the potential for several types of bias, therefore this prospective cohort study attempted to determine whether precise risk estimates could be made using these genetic association […]

Read More…

Evidence mounts to RE-LY on dabigatran

Dabigatran etecxilate is a novel anti-coagulant that acts a direct thrombin inhibitor and provides stable anticoagulation at a fixed dose without any need for a laboratory control. In the RE-LY trial (Randomised Evaluation of Long-term Anticoagulation Therapy), dabigatran was shown to reduced strokes and peripheral embolic events in patients with atrial fibrillation when compared to […]

Read More…

No benefit seen from low dose heparin in PCI

In the OASIS-5 trial (Organzation to Assess Strategies in Acute Ischaemic Syndromes), fondaparinux was found to be non-inferior to enoxaparin for the primary outcome, but was noted to halve major bleeding, leading to a significant mortality reduction. However, a small but significant increase in catheter-related thromboses was also seen, therefore the FUTURA/OASIS-8 trial was set […]

Read More…